Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial

Socrates Papapoulos, Henry Bone, Felicia Cosman, David W Dempster, Michael R McClung, Toshitaka Nakamura, José Fernando Molina Restrepo, Mary L Bouxsein, Dosinda Cohn, Anne de Papp, Rachid Massaad, Arthur Santora, Socrates Papapoulos, Henry Bone, Felicia Cosman, David W Dempster, Michael R McClung, Toshitaka Nakamura, José Fernando Molina Restrepo, Mary L Bouxsein, Dosinda Cohn, Anne de Papp, Rachid Massaad, Arthur Santora

Abstract

We prospectively assessed, with predefined criteria, the location and rates of all femur fractures (hip, subtrochanteric/femoral shaft [ST/FS], including atypical [AFF] and distal fractures) in women at increased fracture risk during treatment with the cathepsin K inhibitor, odanacatib (ODN), or placebo over 5 years in the Long-Term ODN Fracture Trial (LOFT and LOFT Extension [NCT00529373, EudraCT 2007-002693-66]). ODN was an investigational antiresorptive agent previously in development as an osteoporosis treatment that, unlike bisphosphonates, reduces bone formation only transiently. Women aged ≥65 years with a bone mineral density (BMD) T-score ≤-2.5 at the total hip (TH) or femoral neck (FN) or with a radiographic vertebral fracture and T-scores ≤-1.5 at the TH or FN were randomized (1:1) to receive ODN 50 mg/week or placebo. All patients received vitamin D3 (5600 IU/week) and calcium (total 1200 mg/d); the analysis included 16,071 women. Rates of all adjudicated low-energy femoral fractures were 0.38 versus 0.58/100 patient-years for ODN and placebo, respectively (hazard ratio [HR] = 0.65; 95% confidence interval [CI] 0.51-0.82; nominal p < .001), and for low-energy hip fractures were 0.29 versus 0.56/100 patient-years, respectively (HR = 0.52; 95% CI 0.40-0.67; p < .001). The cumulative incidence of combined hip and ST/FS or hip fractures alone in the ODN group was consistently lower than in the placebo group (1.93% versus 3.11% for combined fractures and 1.53% versus 3.03% for hip fractures at 5 years, respectively). However, low-energy ST/FS fractures were more frequent in ODN-treated women than in placebo-treated women (24 versus 6, respectively). Among these, 12 fractures were adjudicated as AFF in 10 patients treated with ODN (0.03/100 patient-years) compared with none in the 6 placebo-treated women (estimated difference 0.03; 95% CI 0.02-0.06). These results provide insight into possible pathogeneses of AFF, suggesting that the current criteria for diagnosing these fractures may need to be reconsidered. © 2021 American Society for Bone and Mineral Research (ASBMR)..

Keywords: BIOCHEMICAL MARKERS OF BONE TURNOVER; CLINICAL TRIALS; OSTEOPOROSIS; THERAPEUTICS.

© 2021 American Society for Bone and Mineral Research (ASBMR).

References

    1. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267-2294.
    1. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23.
    1. Nieves JW, Bilezikian JP, Lane JM, et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int. 2010;21(3):399-408.
    1. Salminen S, Pihlajamaki H, Avikainen V, Kyro A, Bostman O. Specific features associated with femoral shaft fractures caused by low-energy trauma. J Trauma. 1997;43(1):117-122.
    1. Rizzoli R, Akesson K, Bouxsein M, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group report. Osteoporos Int. 2011;22(2):373-390.
    1. Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev. 2019;40(2):333-368.
    1. Bilezikian J, Klemes A, Silverman S, Cosman F. Subtrochanteric fracture reports coincident with risedronate use. J Bone Miner Res. 2009;24(Suppl 1):S469. MO0354.
    1. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761-1771.
    1. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417-1427.
    1. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-523.
    1. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532-1543.
    1. Duong le T, Leung AT, Langdahl B. Cathepsin K inhibition: a new mechanism for the treatment of osteoporosis. Calcif Tissue Int. 2016;98(4):381-397.
    1. McClung MR, O'Donoghue ML, Papapoulos SE, et al. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT extension study. Lancet Diabetes Endocrinol. 2019;7(12):899-911.
    1. Bone HG, Dempster DW, Eisman JA, et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int. 2015;26(2):699-712.
    1. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25(5):937-947.
    1. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89(3):349-353.
    1. Yavropoulou MP, Giusti A, Ramautar SR, Dijkstra S, Hamdy NA, Papapoulos SE. Low-energy fractures of the humeral shaft and bisphosphonate use. J Bone Miner Res. 2012;27(6):1425-1431.
    1. Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf). 2010;72(2):161-168.
    1. Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res. 2012;27(11):2251-2258.
    1. Rizzoli R, Benhamou CL, Halse J, et al. Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study. Osteoporos Int. 2016;27(6):2099-2107.
    1. Mullard A. Merck & Co. drops osteoporosis drug odanacatib. Nat Rev Drug Discov. 2016;15(10):669.
    1. Hashem J, Krochak R, Culbertson MD, Mileto C, Goodman H. Atypical femur fractures in a patient with pycnodysostosis: a case report. Osteoporos Int. 2015;26(8):2209-2212.
    1. Song HK, Sohn YB, Choi YJ, Chung YS, Jang JH. A case report of pycnodysostosis with atypical femur fracture diagnosed by next-generation sequencing of candidate genes. Medicine. 2017;96(12).
    1. Yates CJ, Bartlett MJ, Ebeling PR. An atypical subtrochanteric femoral fracture from pycnodysostosis: a lesson from nature. J Bone Miner Res. 2011;26(6):1377-1379.
    1. Yuasa T, Maeda K, Kaneko K, Yoshikata K. Total hip arthroplasty after treatment of an atypical subtrochanteric femoral fracture in a patient with pycnodysostosis. Case Rep Orthop. 2015;2015:731910.
    1. Roth VG. Pycnodysostosis presenting with bilateral subtrachanteric fractures: case report. Clin Orthop Relat Res. 1976;117:247-253.
    1. Morin S, Wall M, Belzile E, et al. Characterization of >100 patients with atypical femur fractures: the Quebec atypical femur fracture registry. J Bone Miner Res. 2017;32:S4.1015.
    1. LeBlanc ES, Rosales AG, Black DM, et al. Evaluating atypical features of femur fractures: how change in radiological criteria influenced incidence and demography of atypical femur fractures in a community setting. J Bone Miner Res. 2017;32(11):2304-2314.
    1. Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michaelsson K, Aspenberg P. Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone. 2013;52(1):389-392.
    1. Recker R, Dempster D, Langdahl B, et al. Effects of odanacatib on bone structure and quality in postmenopausal women with osteoporosis: 5-year data from the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its extension. J Bone Miner Res. 2020;35(7):1289-1299.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera